Strategic Acquisitions coupled with Advancements in Technology is Expected to Drive the Global Bisacodyl Market Growth

Published: Mar 2022

The global bisacodyl market is anticipated to grow at a considerable CAGR of 5.9 % during the forecast period (2022- 2028). Innovations coupled up with many leading technological advancements and key acquisitions are anticipated to drive the global bisacodyl over the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in July 2020, LMG Pharma acquired formulation development and drug product contract manufacturing process from Nexgen Pharma Inc. The combination brings together LGM Pharma's global leadership in Active Pharmaceutical Ingredient (API), sourcing, distribution, and supply chain management with Nexgen Pharma Inc. drug product contract development and manufacturing services. Furthermore, in February 2020 Dr. Reddy’s Laboratories, Ltd acquired selected divisions of Wockhardt, Ltd branded generic business in India and few other international territories of Nepal, Srilanka, Bhutan, and the Maldives. Multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, pain, and vaccines have been transferred to Dr. Reddy’s Laboratories Ltd along with related sales and marketing teams.

Browse the full report description of “Global Bisacodyl Market Size, Share & Trends Analysis Report by Type (High Purity and Low Purity), by Application (Constipation and Neurogenic Bowl Dysfunction) Forecast 2022-2028.” at https://www.omrglobal.com/industry-reports/bisacodyl-market

Moreover, in May 2021, a Duke Scientist developed an artificial intelligence tool that can be added to the standard toilet to help analyze patient’s stool and give gastroenterologists the information they need to provide appropriate treatment for chronic issues such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The work is in the process by Dukes University’s Centre for Water, Sanitisation, Hygiene and Infectious Disease (wash-AID). Thus advancement in technology is expected to propel the growth of the global bisacodyl market.

Market Coverage

The market number available for – 2022-2028

Base year- 2020

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application 

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Cipla ltd., Dr. Reddy’s Laboratories, GlaxoSmithKline plc, LMG Pharma, Sanofi S.A among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Bisacodyl Market Report Segment

By Type

High purity

Low purity 

By Application 

Constipation 

Neurogenic Bowel Dysfunction  

Global Bisacodyl Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/bisacodyl-market